PPT-Ombitasvir-Paritaprevir-Ritonavir

and Dasabuvir RBV in GT1 SAPPHIREI Phase 3 Treatment Naïve Feld JJ et al N Engl J Med 201437015941603 Source Feld JJ et al N Engl J Med 201437015941603 OmbitasvirParitaprevirRitonavir . -Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . Co-formulated . ombitasvir. (OBV)/. paritaprevir. (PTV)/. rironavir. (r) :. 25/150/100 mg QD = 2 tablets. Dasabuvir. (DSV) : 250 mg bid. Objective. SVR. 12. (HCV RNA < 25 IU/ml). TURQUOISE-III . OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation**. 1 : 1. Open-label. 18-70 years. HCV genotype 1. Naïve or pre-treated. Cirrhosis*. Child-Pugh A < 7. HCV RNA ≥ 10,000 IU/ml. Paritaprevir. -. Ritonavir. . and . Dasabuvir. +/- RBV in GT1. PEARL-III and PEARL-IV. Phase 3. . Treatment. . Naïve. Ferenci. P, et al. N . Engl. J Med. 2014;370:1983-92.. Source: . Ferenci. . Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . Study. : . o. mbitasvir/paritaprevir/ritonavir. . + . d. asabuvir. . + . ribavirin. . for genotype 1. Treatment regimens. Co-formulated . ombitasvir. . + Dasabuvir) + RBV in GT1 . TURQUOISE-I. Phase . 2 . Treatment. Naïve and Treatment . Experienced. Wyles. D, et al. 65. th. AASLD. 2014: Abstract . 1939. . . HIV Coinfection. Source: . Wyles. D, et al. 65. OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open label. 18-70 years. Chronic HCV infection. Genotype 4 . Treatment-naïve or failure . t. o PEG-IFN + RBV. HCV RNA > 10,000 IU/ml. No cirrhosis**. No HBV or HIV co-infection. Updated: . July . 6. , . 2015. Treatment of Hepatitis C in Patients with Renal Insufficiency. Robert G. Gish MD. Professor Consultant, Stanford University Medical Center. Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona. PATENTSCOPE. September. 2016. Sandrine Ammann. Marketing & Communications Officer. To this webinar:. Chemical structure search. Agenda. Chemical structure search. Timeline. Access . How . does. . Prepared by: . Sophie . Woolston. , MD and David H. Spach, MD. Last . Updated: . November 18, 2014. 3D. Background and Dosing. 3D (. Paritaprevir. -Ritonavir-. Ombitasvir. + . Dasabuvir. ). 3D (. Paritaprevir. AI424-043 . Study. Atazanavir vs. Lopinavir-ritonavir in Previous PI Failure . AI424-043. : Study Design. Source: . Cohen C, et al. . Curr Med Res Opin. . 2005;21:. 1683-92.. Atazanavir 400 mg once daily + 2 NRTIs. Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC. NEAT001/ANRS143: Study Design. Source: . Raffi. F, et al. Lancet. 2014;384:1942-51. .. Darunavir + Ritonavir QD. + Raltegravir BID .